Revelation Biosciences (REVB) executive compensation, 2026 proxy

James Rolke, Chairman, Director, and CEO, was paid $1.5M in 2025, up 87% from $813,226 the year before.

Filed
May 11, 2026
Annual meeting
June 24, 2026
Pay year
2025
Named executives
2
CEO total pay
$1.5M+87% vs prior year
CEO pay in equity
42%$639,890 in awards
CEO stock awards
$639,8902025 stock-based awards
CFO total compensation
$1,185,4092025 Summary Compensation Table
CEO compensation actually paid
$1,197,0562025 pay-versus-performance disclosure
CFO compensation actually paid
$916,1652025 pay-versus-performance disclosure
Unvested award value
$312,415For each executive at year-end
CEO bonus
$280,500Paid during fiscal 2026

How Rolke was paid

$1.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary39%Bonus18%Stock awards42%All other compensation1%

Named executive officers

ExecutiveTotal
James RolkeChairman, Director, and CEO$1,524,532
Chester S. Zygmont, IIICFO$1,185,409

What changed and why

  • $1.5M2025 CEO total compensation was $1,524,532 versus $813,226 in 2024.
  • $640K2025 CEO stock-based awards were $639,890; CFO stock-based awards were $581,659.
  • $281K2025 bonuses were $280,500 for the CEO and $162,000 for the CFO, paid during fiscal 2026.
  • $312KOctober 28, 2025 stock awards had $312,415 in market or payout value for each executive.
  • The company stated it has no pension plan; awards vest quarterly over one year.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.